Beta Bionics financials
$19.41−5.41%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 |
|---|---|---|---|---|---|---|
| Revenue | $32.0M | $27.6M | $32.1M | $27.3M | $23.2M | $17.6M |
| Gross profit | $18.9M | $16.4M | $18.9M | $15.1M | $12.5M | $9.0M |
| Gross margin | 59.0% | 59.5% | 59.0% | 55.5% | 53.8% | 50.9% |
| Operating income | -$25.6M | -$24.3M | -$16.1M | -$17.0M | -$19.9M | -$18.6M |
| Net income | -$23.4M | -$21.9M | -$13.5M | -$14.2M | -$16.9M | -$28.7M |
| Net margin | −73.1% | −79.3% | −41.9% | −52.1% | −72.6% | −162.5% |
| Diluted EPS | $-0.53 | $-0.49 | $-0.30 | $-0.33 | $-0.39 | $-0.93 |
| EBITDA | -$24.9M | -$23.7M | -$15.6M | -$16.7M | -$19.5M | -$18.3M |
| Operating cash flow | -$14.6M | -$23.8M | -$8.6M | -$8.7M | -$13.6M | -$20.0M |
| Free cash flow | -$15.7M | -$25.2M | -$10.5M | -$10.0M | -$15.4M | -$20.3M |
| Diluted shares | 44.5M | 44.4M | 44.4M | 43.6M | 43.4M | 30.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $44.3M | $30.2M | $31.6M | $38.5M | $35.1M | $42.5M |
| Short-term investments | $136.2M | $169.3M | $187.5M | $190.2M | $214.6M | $189.0M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $292.4M | $304.4M | $328.7M | $330.0M | $330.0M | $338.0M |
| Total liabilities | $36.0M | $33.2M | $41.1M | $35.3M | $28.3M | $24.3M |
| Shareholders' equity | $256.4M | $271.2M | $287.6M | $294.8M | $301.6M | $313.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology